earnings
confidence high
sentiment positive
materiality 0.80
MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance
MIMEDX GROUP, INC.
2025-Q3 EPS reported
$0.22
revenue$300,535,000
- Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.
- Adjusted EBITDA $35M, 31% of net sales; Wound product sales grew 40%, Surgical 26%.
- Cash and equivalents $142M at Sept 30, up from $104M at Dec 31, 2024.
- 2025 outlook raised: net sales growth mid-to-high teens, adjusted EBITDA margin at least mid-20%.
- CEO cites record revenue, cash flow; awaiting final 2026 CMS reimbursement rules.